ウィメンズヘルス向け医薬品市場（種類別、薬剤別、用途別、地域別）：将来予測（2026～2032年）

ウィメンズヘルス向け医薬品市場の評価（2026～2032年）

より多くの情報とエンパワーメントにより、ウィメンズヘルスに対する知識とアドボカシーの必要性が高まり、女性は健康上の懸念に対処するための医療介入をより積極的に求めるようになっています。このような意識の高まりは、生殖の健康、更年期管理、ホルモンバランスの乱れなどの問題に対処するために設計された医薬品に対する需要の増加をもたらし、2023年には229億8,904万米ドルの売上高を突破し、2032年には529億4,094万米ドルの評価額に達することを可能にしています。

薬による介入に対するニーズの高まりは、女性の健康のみを対象としています。性別特有の健康課題を理解し、それに取り組むという文化的態度に大きな変化が見られ、その結果、女性特有の生理的・生殖的ニーズに的を絞った完全なヘルスケアソリューションの提唱が増加しています。このような世論の変化は、製薬会社が生殖に関する健康問題、ホルモンバランスの乱れ、更年期症状などの疾患に対する医薬品や治療法の開発に重点を置いた研究開発に投資することを促し、市場は2026年から2032年にかけてCAGR 10.99%で成長することになりました。

ウィメンズヘルス向け医薬品市場：定義/概要

ウィメンズヘルス向け医薬品とは、女性特有の、あるいは女性が主に罹患する様々な健康障害や状態に対処するために特別に設計された医薬品や治療を指します。これらの医薬品には、生殖の健康、ホルモンバランスの乱れ、更年期症状、避妊、不妊治療、骨粗鬆症や一部のがんのような主に女性が罹患する疾患の改善を目的とした幅広い製品が含まれます。これらの医薬品は、男女間の生物学的・ホルモン学的な違いや、女性が生涯を通じて直面する可能性のある特有の健康上の困難やニーズに対応するように設計されています。

ウィメンズヘルス向け医薬品には、人生の様々な段階における女性の個々の生理学的・ヘルスケア的要求に対応する幅広い用途があります。生殖に関する健康からホルモンバランスに至るまで、医薬品の介入は様々な医学的障害を治療し、全体的な幸福感を高める上で重要な役割を果たしています。

妊産婦ケアにおける医薬品の進歩は、出生前の問題、妊産婦の栄養、出生前診断に焦点を当てた治療法の開発によって、妊娠転帰と妊産婦の幸福を改善することが期待されています。妊娠糖尿病の革新的な治療薬から先進的な出生前スクリーニング技術に至るまで、妊産婦用医薬品の将来は、リスクを減少させ、母体と胎児の健康状態を改善し、その結果、妊産婦の罹患率と死亡率を減少させることが期待されています。

女性の生物学的な悩みの増加は、ウィメンズヘルス市場を牽引するか？

女性の生物学的問題の増加は、女性の健康市場に重要な影響を与えると予測されます。多くの人口動態セグメントにおいて、女性特有の健康上の要求や懸念が認識されつつあり、これらの問題に対処するために設計された専門的なヘルスケアソリューションに対する需要が高まっています。このような意識の高まりは、医学研究と技術の進歩とともに、ウィメンズヘルス産業の著しい成長を促進すると予想されます。

世界中の女性の間で生殖に関する健康上の問題や懸念が増加していることが、この動向を後押ししている主な原因のひとつです。不妊症、月経の問題、生殖器がんは、専門家の介入や治療を必要とする一般的な健康問題として生じています。また、社会やライフスタイルの変化により、家族計画やリプロダクティブヘルスケアが重視されるようになり、ウィメンズヘルスサービス・製品に対する需要が高まっています。女性の生物学的な悩みの増加は、進化する社会的態度や技術の進歩と相まって、ウィメンズヘルス市場の著しい成長を促進するものと思われます。

研究開発に伴う高コストは、ウィメンズヘルス市場の妨げになるか？

研究開発に伴うコストは、市場発展の大きな障壁となります。研究開発の熟練度を発展・向上させるには、多額の資金を投入する必要があり、多くの市場ベースの組織にプレッシャーを与える可能性があります。また、資金不足は、新しい医療技術やシステムを統合し、維持する上での障害となります。農村部や低開発地域などインフラが不十分な場所では、最新の医療施設や医療機器へのアクセスが著しく制限される場合があり、女性医学やその他の関連技術の普及を妨げています。

大きな問題は、女性向け医療にかかる費用の高さです。これらの費用は、研究開発、製造、流通を含む幅広い分野に及んでおり、これらすべてがエンドユーザーの価格上昇の原因となっています。このような高コストのために、特にヘルスケアを受けられるかどうかが大きな問題となっている低所得者層では、こうした医療ソリューションに多くの人々がアクセスできない可能性があります。さらに、新興諸国における女性用医薬品の意義と入手可能性についての理解不足が、市場への浸透と採用率の制限という問題を悪化させています。

目次

第1章 世界のウィメンズヘルス向け医薬品市場：イントロダクション

• 市場概要
• 分析範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの分析手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界のウィメンズヘルス向け医薬品市場の展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 世界のウィメンズヘルス向け医薬品市場：種類別

• 概要
• 医薬品
• 機器

第6章 世界のウィメンズヘルス向け医薬品市場：用途別

• 概要
• ホルモン性不妊症
• 閉経後骨粗鬆症
• 子宮内膜症
• 避妊薬
• 更年期障害
• 多嚢胞性卵巣症候群

第7章 世界のウィメンズヘルス向け医薬品市場：薬剤別

• 概要
• プロリア
• XGEVA
• エビスタ
• ミレーナ
• ゾメタ
• リクラスト/アクラスタ
• ミナストリン24Fe
• フォルテオ
• ヌーバリング
• プリマリン
• アクトネル
• オルト・トライシー・エルオー（28）

第8章 世界のウィメンズヘルス向け医薬品市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋
• その他の地域 (ROW)
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界のウィメンズヘルス向け医薬品市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第10章 企業プロファイル

• Siemens
• Hologic, Inc.
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Abbott
• BD
• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific, Inc.
• Koninklijke Philips N.V.
• NeuroLogica Corp.
• Shimadzu Medical pvt. Ltd.
• GENERAL ELECTRIC.
• Quest Diagnostics Incorporated
• Sysmex India Pvt. Ltd
• Hitachi Ltd.
• Canon Inc.
• FUJIFILM Holdings Corporation

第11章 主な動向

• 製品上市/開発
• 企業合併・買収 (M&A)
• 事業拡大
• 提携・協力

第12章 付録

• 関連分析

Pharmaceuticals For Women's Health Market Valuation - 2026-2032

The increasing need for knowledge and advocacy for women's health issues with more information and empowerment, women are becoming more proactive in seeking medical interventions to address their health concerns. This increased awareness has resulted in a growing demand for pharmaceutical medications designed to address issues such as reproductive health, menopausal management, and hormonal imbalances by enabling the market to surpass a revenue of USD 22989.04 Million in 2023 and reach a valuation of around USD 52940.94 Million by 2032.

The increasing need for medicinal interventions is aimed only at women's health. There has been a significant shift in cultural attitudes toward understanding and addressing gender-specific health challenges resulting in increased advocating for complete healthcare solutions targeted to women's distinct physiological and reproductive needs. This changing public discourse has encouraged pharmaceutical companies to invest in research and development efforts focused on creating medicines and therapies for diseases such as reproductive health issues, hormonal imbalances, and menopausal symptoms by enabling the market to grow at a CAGR of 10.99% from 2026 to 2032.

Pharmaceuticals For Women's Health Market: Definition/ Overview

The term pharmaceuticals for women's health refers to medications and treatments that are specifically designed to address various health disorders and conditions that are unique to or mostly affect women. These medications may include a wide range of products aimed at improving reproductive health, hormonal imbalances, menopausal symptoms, contraception, fertility therapies, and illnesses such as osteoporosis and some types of cancer that primarily affect women. These medications are designed to address the different biological and hormonal differences between men and women as well as the unique health difficulties and needs that women may confront throughout their lifetimes.

The pharmaceuticals for women's health include a wide range of applications that address the individual physiological and healthcare demands of women at various phases of life. From reproductive health to hormonal balance and beyond pharmaceutical interventions play an important role in treating a variety of medical disorders and boosting overall well-being.

The pharmaceutical advances in maternal care are expected to improve pregnancy outcomes and maternal well-being by developing focused therapies for prenatal problems, maternal nutrition, and prenatal diagnostics. From innovative treatment agents for gestational diabetes to advanced prenatal screening technologies, the future of maternal pharmaceuticals holds promise for decreasing risks and improving mother-fetal health outcomes; therefore, reducing maternal morbidity and mortality rates.

Will the Increasing Prevalence of Women's Biological Concerns Drive the Women's Health Market?

The increasing number of women's biological problems is predicted to have an important effect on the female health market. Across many demographic segments, there is a growing acknowledgment of women's particular health demands and concerns increasing demand for specialized healthcare solutions designed to address these issues. This increased awareness together with advances in medical research and technology is expected to fuel significant growth in the women's health industry.

The rising incidence of reproductive health difficulties and concerns among women around the world is one of the key causes driving this trend. Infertility, menstrual problems, and reproductive cancers have arisen as common health issues that require specialist interventions and treatments. Also, social and lifestyle changes have resulted in a greater focus on family planning and reproductive healthcare increasing demand for women's health services and products. The increasing prevalence of women's biological concerns, coupled with evolving social attitudes and technological advancements is controlled to drive significant growth within the women's health market.

Will the High Cost Associated with Research and Development Hamper the Women's Health Market?

The costs associated with research and development efforts present a significant barrier to market advancement. Developing and improving R&D proficiency requires significant financial dedication which may put pressure on many market-based organizations. Also, inadequate funding creates obstacles to integrating and maintaining new medical technologies and systems. Access to contemporary medical facilities and equipment may be severely limited in locations with inadequate infrastructure such as rural or underdeveloped areas hindering the widespread adoption of women's medicine and other associated technology.

The major issue is the high expense of women's medicine. These expenses cover a wide range of areas including research and development, manufacturing, and distribution all of which contribute to higher prices for end users. Such high costs may make these medical solutions inaccessible to a large segment of the population particularly in low-income areas where healthcare affordability is a major concern. Furthermore, a lack of understanding about the significance and availability of women's medicine in developing countries exacerbates the problem of limiting market penetration and adoption rates.

Category-Wise Acumens

Will the Increasing Prevalence of Women's Biological Concerns Drive the Pharmaceuticals For Women's Health Market?

The drugs for women's health industry are expected to increase rapidly as women's biological issues become more prevalent. This rising trend is driven by a variety of factors ranging from shifting opinions in society to advances in medical science and technology. Passive variables such as cultural developments toward recognizing and addressing women's health issues are critical in increasing demand for pharmaceutical solutions customized specifically to women's needs. Also, the acknowledgment and understanding of the unique biological obstacles that women experience at various phases of their lives has prompted increased research and development activities in the pharmaceutical business.

The increasing focus on women's health is highlighted by the rising occurrence of illnesses such as hormonal imbalances, reproductive health issues, and menopausal symptoms, all of which require specialist treatment choices. Also, women's growing understanding and empowerment about their health and well-being have fueled the desire for pharmaceutical therapies that address their unique physiological demands. In addition, regulatory actions targeted at encouraging women to participate in clinical trials and healthcare policy have contributed to the development and availability of medications that address women's health concerns. Therefore, the Pharmaceuticals For Women's Health Market is expected to grow significantly as it continues to serve women's evolving healthcare demands around the world.

Will the Risk of Osteoporosis Fractures Support the Growth of the Women's Health Market?

The risk of osteoporosis fractures is anticipated to contribute significantly to the expansion of the women's health market. Within this domain, a multitude of factors converge to underscore the critical importance of addressing osteoporosis as a prevalent health concern among women. Passive lifestyle patterns, hormonal changes associated with menopause, and genetic predispositions collectively elevate the vulnerability of women to osteoporotic fractures. This heightened susceptibility not only poses significant health risks but also imposes substantial economic burdens on healthcare systems worldwide.

The increased awareness of osteoporosis-related fractures has increased demand for enhanced diagnostic technology and novel treatment options. This has sparked significant research and development activities aiming at improving the efficacy of current medicines while also exploring new therapeutic approaches. Passive support for market expansion comes from the growing use of evidence-based recommendations and clinical procedures that stress proactive screening and early intervention measures.

Country/Region-wise Acumens

Will the Increasing Investment in Research and Development be the Opportunistic Factor for North America?

North America is expected to continue establishing its dominance in the worldwide Pharmaceuticals For Women's Health Market as it currently holds the greatest market share. This dominance can be given to numerous variables. There has been a noticeable increase in focus to women's therapeutics in the region demonstrating a greater awareness and prioritization of women's health concerns. This increased attention is accompanied by a similar increase in funding for the research and development of novel treatments, techniques, and medications to address women's health concerns. Such expenditures demonstrate a commitment to advance medical science and improve healthcare outcomes for women of all ages and medical conditions.

The presence of world-class medical institutes and healthcare facilities strengthens North America's leadership in pharmaceuticals for women's health. Healthcare professionals and researchers in the region have access to a variety of experience, resources, and innovative technology, allowing them to drive innovation and offer superior healthcare results for female patients. This excellent ecosystem promotes collaboration, knowledge exchange, and the quick translation of scientific discoveries into clinical applications putting North America at the forefront of the global pharmaceutical landscape for women's health.

Therefore, North America's dominance in the Pharmaceuticals For Women's Health Market is based on several factors including an increased focus on women's therapeutics, significant investments in research and development, a commitment to safety measures, an increase in the prevalence of women's health conditions, and the presence of world-class medical institutions.

How will the Pharmaceuticals For Women's Health Market Favor in Asia Pacific?

Demographic dynamics such as population increase, aging populations, and changing lifestyles all contribute to the region's growing demand for women's health drugs. As the population ages, there is a greater need for therapies and drugs that address menopausal symptoms, osteoporosis, and other age-related illnesses impacting women. Also, lifestyle variables such as increased stress, sedentary lifestyles, and changing eating habits contribute to the development of obesity, diabetes, and cardiovascular disease in women boosting demand for relevant pharmaceutical therapies.

The advancement in medical research and technology is projected to drive innovation in women's health pharmaceuticals resulting in the creation of new medications and cures. This includes advances in reproductive health, contraception, fertility therapies, and gynecological diseases like endometriosis and polycystic ovary syndrome. Pharmaceutical company's continuous efforts to invest in research and development primarily aimed at women's health issues are expected to help market expansion in Asia Pacific.

The medicines for women's health market in the Asia Pacific is expected to expand due to a variety of factors. The region's increasing focus on healthcare and well-being combined with increased awareness of women's health challenges is expected to drive demand for pharmaceutical goods modified to women's special needs. This increased awareness is supported by the efforts of governments, healthcare institutions, and advocacy organizations that are actively advocating measures to address women's health issues.Competitive Landscape

The Pharmaceuticals For Women's Health Market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the Pharmaceuticals For Women's Health Market include:

Siemens, Hologic Inc., Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Abbott, BD, Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Koninklijke Philips N.V., NeuroLogica Corp., Shimadzu Medical pvt. Ltd., GENERAL ELECTRIC, Quest Diagnostics Incorporated, Sysmex India Pvt. Ltd., Hitachi Ltd., Canon Inc., FUJIFILM Holdings Corporation

Latest Developments

In December 2020, Pfizer, Inc., and Myovant Sciences worked on the commercialization and development of Relugolix, the first and only oral GnRH antagonist for oncology and women's health.

In September 2020, Bayer increased its range of women's healthcare products by acquiring KaNDy Therapeutics Ltd. Menopausal vasomotor symptoms affect up to 75% of women who are transitioning into menopause. These symptoms can disrupt both their professional and private life and are devastating for several years for people affected, resulting in major additional healthcare and economic costs.

Pharmaceuticals For Women's Health Market, By Category

• Type:
• Drugs
• Devices
• Drug:
• Prolia
• XGEVA
• EVISTA
• Mirena
• Zometa
• Reclast or Aclasta
• Minastrin 24 Fe
• FORTEO
• NuvaRing
• Primarin
• ACTONEL
• ORTHO TRI-CY LO (28)
• Application:
• Hormonal Infertility
• Postmenopausal Osteoporosis
• Endometriosis
• Contraceptives
• Menopause
• Polycystic Ovary Syndrome
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PHARMACEUTICALS FOR WOMEN'S HEALTH MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL PHARMACEUTICALS FOR WOMEN'S HEALTH MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL PHARMACEUTICALS FOR WOMEN'S HEALTH MARKET, BY TYPE

• 5.1 Overview
• 5.2 Drugs
• 5.3 Devices

6 GLOBAL PHARMACEUTICALS FOR WOMEN'S HEALTH MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Hormonal Infertility
• 6.3 Postmenopausal Osteoporosis
• 6.4 Endometriosis
• 6.5 Contraceptives
• 6.6 Menopause
• 6.7 Polycystic Ovary Syndrome

7 GLOBAL PHARMACEUTICALS FOR WOMEN'S HEALTH MARKET, BY DRUG

• 7.1 Overview
• 7.2 Prolia
• 7.3 XGEVA
• 7.4 EVISTA
• 7.5 Mirena
• 7.6 Zometa
• 7.7 Reclast or Aclasta
• 7.8 Minastrin 24 Fe
• 7.9 FORTEO
• 7.10 NuvaRing
• 7.11 Primarin
• 7.12 ACTONEL
• 7.13 ORTHO TRI-CY LO (28)

8 GLOBAL PHARMACEUTICALS FOR WOMEN'S HEALTH MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Paciic
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL PHARMACEUTICALS FOR WOMEN'S HEALTH MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Siemens
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Hologic, Inc.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Abbott
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 BD
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 F. Hoffmann-La Roche Ltd
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Thermo Fisher Scientific, Inc.
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Koninklijke Philips N.V.
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 NeuroLogica Corp.
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Shimadzu Medical pvt. Ltd.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments
• 10.11 GENERAL ELECTRIC.
  • 10.11.1 Overview
  • 10.11.2 Financial Performance
  • 10.11.3 Product Outlook
  • 10.11.4 Key Developments
• 10.12 Quest Diagnostics Incorporated
  • 10.12.1 Overview
  • 10.12.2 Financial Performance
  • 10.12.3 Product Outlook
  • 10.12.4 Key Developments
• 10.13 Sysmex India Pvt. Ltd
  • 10.13.1 Overview
  • 10.13.2 Financial Performance
  • 10.13.3 Product Outlook
  • 10.13.4 Key Developments
• 10.14 Hitachi Ltd.
  • 10.14.1 Overview
  • 10.14.2 Financial Performance
  • 10.14.3 Product Outlook
  • 10.14.4 Key Developments
• 10.15 Canon Inc.
  • 10.15.1 Overview
  • 10.15.2 Financial Performance
  • 10.15.3 Product Outlook
  • 10.15.4 Key Developments
• 10.16 FUJIFILM Holdings Corporation
  • 10.16.1 Overview
  • 10.16.2 Financial Performance
  • 10.16.3 Product Outlook
  • 10.16.4 Key Developments6

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research